Cigna Group (CI) Q3 2026 Earnings Call Transcript

Cigna reported third-quarter adjusted revenue of $73.8 billion, up 6% year over year, and adjusted EPS of $7.98 versus $7.83 a year earlier; it raised its 2026 adjusted EPS floor to $30.60. Management expects at least 10% adjusted EPS growth in 2027 from an approximately $30 run-rate baseline, while forecasting a $200 million ACA-exchange-exit headwind and low-single-digit Evernorth earnings growth. Specialty and Care Services is expected to grow 8%–12% in 2027, near the low end, while Pharmacy Benefit Services faces rebate and GLP-1 coverage pressures.

Analysis

The earnings quality is more mixed than the upbeat full-year revision suggests. The 2027 growth bridge relies on Cigna Healthcare margin execution and a recovery in Pharmacy Benefit Services after rebate compression and lower employer GLP-1 coverage; the Signature transition is not yet a near-term earnings catalyst. Its 2028 adoption ramp depends on manufacturer and pharmacy contracts, so treat claimed affordability benefits as unproven until client conversion and unit economics are disclosed. A fee-based model could reduce rebate-related volatility and differentiate Cigna with employers, but may also redistribute economics among PBMs, drugmakers, and pharmacies rather than expand industry profit pools.

Specialty growth is unusually sensitive to the timing of biosimilar launches. A lighter 2027 pipeline is a temporary headwind in management’s framing, while later medical-benefit biosimilars could favor scaled specialty distribution and provider-support capabilities. Conversely, rapid generic substitution can lower revenue per prescription even as it improves affordability; monitor specialty earnings, not adoption rates alone. The ACA exit removes a business and leaves near-term stranded costs, while the stated automation savings are gross and partly reinvested—do not capitalize the full target as incremental margin.

Near term, the raised 2026 outlook supports sentiment, but Q4’s detailed 2027 bridge is the next valuation catalyst. Over 6–18 months, the key risks are MCR deterioration beyond pricing assumptions, weak PBS economics, and execution/regulatory friction around PBM transparency and integration. Consensus may be over-crediting long-dated savings and Signature before evidence; offsetting that, the 2027 specialty pause may be over-extrapolated if later launches materialize.

Key Decisions for Investors

• Maintain a modest long CI bias rather than chase the earnings reaction; add only on post-call weakness if Q4 guidance confirms the 2027 EPS-growth framework without worsening MCR assumptions. Reassess if medical costs rise faster than pricing or management cuts its growth outlook.
• Use the Q4 call as the 1–3 month catalyst check: require segment-level quantification of PBS rebate/GLP-1 headwinds, ACA stranded costs, and savings reinvestment before increasing exposure.
• Track Signature contract completion, employer adoption for 2028, and PBS earnings trajectory. If adoption lags or PBS declines exceed the guided transition, reduce the long; if conversions and economics are demonstrated, the model could support a higher-quality, less rebate-dependent earnings profile.
• Monitor specialty earnings growth and launch timing through 2027–28; do not treat high biosimilar utilization alone as proof of earnings upside. A sustained slowdown below the stated specialty growth range would falsify the temporary-headwind thesis.